Three US Food and Drug Administration-approved therapies for chronic GVHD.

ABSTRACT: Chronic graft-versus-host disease (cGVHD) is a major immunologic complication of allogeneic hematopoietic cell transplantation. cGVHD involves multiple organs, reduces quality of life, and often requires prolonged therapy with glucocorticoids, causing severe side effects. After 4 decades of testing multiple therapeutic approaches, ibrutinib, belumosudil, and ruxolitinib were US Food and Drug Administration approved for cGVHD in the last 4 years. Here we put a spotlight on their mechanisms of action, studies that led to approval, and their future role in cGVHD.

SUBMITTER: Zeiser R 

PROVIDER: S-EPMC8931512 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature